3D Biology: Accelerating Drug Discovery With Danaher Life Sciences

The ongoing demand for new and effective drugs continues to drive the need for extensive research and development (R&D) efforts in the pharmaceutical industry. Bringing a drug to market is a complex and costly process that involves multiple stages, including discovery, preclinical testing, and clinical trials. Despite the significant investment of time and resources, many drug candidates that successfully navigate the early phases of development ultimately fail during clinical trials due to issues such as lack of efficacy or unforeseen side effects. This high attrition rate underscores the importance of improving the efficiency and accuracy of drug screening methods. To address these challenges, there is a growing emphasis on developing cost-effective technologies that can more accurately replicate human physiological responses.

Explore how such advancements could enhance the predictive power of preclinical testing, reduce the likelihood of failure in later stages, and ultimately accelerate the delivery of safe and effective therapies to patients.